Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
P409195-1ml
|
1ml |
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
|
$83.90
|
|
DHFR Inhibitors
| Synonyms | 5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine |
|---|---|
| Specifications & Purity | Moligand™, 10mM in DMSO |
| Biochemical and Physiological Mechanisms | Pyrimethamine is a dihydrofolate reductase (DHFR) inhibitor, used as an antimalarial drug. |
| Storage Temp | Store at -80°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Grade | Moligand™ |
| Product Description |
Information Pyrimethamine Pyrimethamine is a dihydrofolate reductase (DHFR) inhibitor, used as an antimalarial drug. Pyrimethamine has an IC50 of 5–13 μM for the Hex isozymes at pH 4.3. Pyrimethamine increases the enzyme activity and protein level of the α and β subunits of Hex A in the βR505Q/Δ16kb cell line. Pyrimethamine-sulfadoxine is an inhibitor of dihydrofolate reductase(DHFR) that has been widely used to treat chloroquine-resistant Plasmodium falciparum malaria. Pyrimethamine is a potent inhibitor of mouse (m)Mate1 (K(i) = 145 nM) among renal organic cation transporters mOctn1 and mOctn2 (K(i) > 30 mM), mOct1 (K(i) = 3.6 mM), and mOct2 (K(i) = 6.0 mM). Pyrimethamine inhibits the uptake of metformin by kidney brush-border membrane vesicles (BBMVs) (K(i) = 41 nM) and canalicular membrane vesicles in the presence of outward gradient of H+. Pyrimethamine treatment significantly increases the kidney-to-plasma ratio of tetraethylammonium, and both the liver- and kidney-to-plasma ratios of metformin in mice, whereas it does not affect their plasma concentrations and urinary excretion rates. Pyrimethamine is a potent inhibitor of human (h)MATE1 and hMATE2-K (K(i) = 77 and 46 nM, respectively) and H+ and organic cation exchanger in human kidney BBMVs (K(i) = 31 nM) in the presence of outward gradient of H+. In vivo
cell lines:Human umbilical vein endothelial cells (HUVECs) Concentrations: Incubation Time: Powder Purity:≥100% |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Smiles | CCC1=NC(=NC(=C1C2=CC=C(Cl)C=C2)N)N |
|---|---|
| Molecular Weight | 248.71 |
| 1. Guanxing Chen, Haohuai He, Lu Zhao, Qiujie Lv, Calvin Yu-Chian Chen. (2024) GINCM-DTA: A graph isomorphic network with protein contact map representation for potential use against COVID-19 and Omicron subvariants BQ.1, BQ.1.1, XBB.1.5, XBB.1.16. EXPERT SYSTEMS WITH APPLICATIONS, 236 (121274). |
| 2. Qian Jingqi, Wang Mian, Wang Zhaoxiang, Feng Rui, Zhang Jiaqi, Ye Chencheng, Zhang Man, Wang Baomin, Cui Liwang. (2022) Development of single- and multiplex immunoassays for rapid detection and quantitation of amodiaquine in ACT drugs and rat serum. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 414 (4): (1631-1640). |
| 3. Jian Lu, Yingying Qin, Yilin Wu, Minjia Meng, Zeqing Dong, Chao Yu, Yongsheng Yan, Chunxiang Li, Felix Kwame Nyarko. (2020) Bidirectional molecularly imprinted membranes for selective recognition and separation of pyrimethamine: A double-faced loading strategy. JOURNAL OF MEMBRANE SCIENCE, 601 (117917). |
| 4. Shuyi Huang, Manli Guo, Lei Tan, Jiean Tan, Jinyi Wu, Youwen Tang, Yong Liang. (2018) Click chemistry-based core–shell molecularly imprinted polymers for the determination of pyrimethamine in fish and plasma samples. Analytical Methods, 10 (23): (2750-2755). |
| 5. Li Peiyao, Su Rina, Ren Ganglin, Si Hongbin, Song Xingju, Hu Dandan. (2025) Molecular mechanisms of surface antigen suppression by ApiAP2 and its implications for vaccine development. VETERINARY RESEARCH, 56 (1): (1-14). |